ID: ALA1170180

Max Phase: Preclinical

Molecular Formula: C10H16FN

Molecular Weight: 169.24

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  NC12CC3CC(C1)CC(F)(C3)C2

Standard InChI:  InChI=1S/C10H16FN/c11-9-2-7-1-8(3-9)5-10(12,4-7)6-9/h7-8H,1-6,12H2

Standard InChI Key:  USUQQGKBGPIRRT-UHFFFAOYSA-N

Associated Targets(non-human)

Matrix protein 2 436 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 169.24Molecular Weight (Monoisotopic): 169.1267AlogP: 2.01#Rotatable Bonds: 0
Polar Surface Area: 26.02Molecular Species: BASEHBA: 1HBD: 1
#RO5 Violations: 0HBA (Lipinski): 1HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 10.63CX LogP: 0.97CX LogD: -1.85
Aromatic Rings: 0Heavy Atoms: 12QED Weighted: 0.59Np Likeness Score: 0.39

References

1. Eleftheratos S, Spearpoint P, Ortore G, Kolocouris A, Martinelli A, Martin S, Hay A..  (2010)  Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model.,  20  (14): [PMID:20570509] [10.1016/j.bmcl.2010.05.049]

Source